Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)

Nov 14, 2022

Vibeke Strand1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1Stanford University School of Medicine, Stanford, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA...

Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)

Nov 13, 2022

Jeffrey Curtis1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1University of Alabama at Birmingham, Hoover, AL, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA...

Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis

Nov 4, 2022

Jeffrey R. Curtis; Vibeke Strand; Steven Golombek; Lixia Zhang; Angus Wong; Mark C. Zielinski; Viatcheslav R. Akmaev; Alif Saleh; Sam Asgarian; and Johanna B. Withers Background The molecular signature response classifier (MSRC) predicts tumor necrosis factor-ɑ...

Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis

Jun 1, 2022

 Johanna Withers, PhD; Lixia Zhang, PhD; Sam Asgarian, MD Presented at EULAR 2022 Copenhagen, Denmark – June 1-4, 2022 Background: Despite drug therapies that improve lives, tens of millions of patients annually are subjected to therapy using a...

Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis

Apr 23, 2022

Vibeke Strand; Lixia Zhang; Alix Arnaud; Erin Connolly-Strong; Sam Asgarian & Johanna B Withers Background A blood-based molecular signature response classifier (MSRC) predicts non-response to tumor necrosis factor-ɑ inhibitors (TNFi) in rheumatoid arthritis (RA)....

Budget Impact and Clinical Outcomes of a Molecular Signature to Inform TNFi Treatment Selection in Commercial Patients with Rheumatoid Arthritis 

Mar 29, 2022

 Martin Bergman, MD; Erin Connolly-Strong, PhD; Alyssa Guidoboni, MScM; Alix Arnaud, MsC  Presented at AMCP 2022 Chicago, Illinois – March 29, 2022 Introduction: • Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic...